American Society of Addiction Medicine
American Society of Addiction Medicine
Lead: Examining the benefit of a higher maintenance dose of extended-release buprenorphine
Lead: Examining the benefit of a higher maintenance dose of extended-release buprenorphine
Lead: Examining the benefit of a higher maintenance dose of extended-release buprenorphine
Tuesday 19th December 2023
Discover new insights on buprenorphine dosages, fentanyl overdose protection, psilocybin for bipolar depression, and more in addiction medicine.
6 minutes
Informative
Empowering
Hopeful
Supportive
Engaging
About this podcast
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Nutritional Pathways to Recovery
Navigating Intimate Relationships
Links:
Visit site
Episodes:
140 (View all)
Do you want to link to this podcast?
Get the buttons here!Buprenorphine Breakthroughs: New Insights on Dosage and Treatment Efficacy
Episode Overview
- Exploration of the impact of a higher maintenance dose of extended-release buprenorphine on opioid-injecting participants
- Insights into the potential protective effects of buprenorphine on fatality risk during acute fentanyl exposures
- Discussion on the use of synthetic psilocybin for treatment-resistant bipolar type 2 major depressive episodes
- Examination of the association between methamphetamine use and aberrations in the compensatory immunoregulatory system
- Pilot study findings on the efficacy of a dynamic norms intervention for reducing young adult alcohol use
This study examined all unintentional deaths involving fentanyl in West Virginia between 2011 and 2020. The presence of metabolite nor buprenorphine suggests that for about 90% of these deaths, the buprenorphine was a chronic medication 90% of these deaths, the buprenorphine was a chronic medication rather than a component of the acute overdose event.
Imagine a world where addiction treatment is more effective and personalized. In this episode of 'This Week in Addiction Medicine', host Claire Rasmussen delves into the benefits of higher maintenance doses of extended-release buprenorphine for those struggling with opioid use disorder. The episode kicks off with a detailed look at a study comparing 100 mg and 300 mg doses, revealing that higher doses significantly improve abstinence and treatment retention for opioid-injecting patients.
This finding could be a game-changer for tailoring treatments to individual needs. But that's not all. Claire also unpacks other intriguing studies, like the potential protective effects of buprenorphine against fatal fentanyl overdoses. You'll hear about synthetic psilocybin's promising role in treating bipolar type 2 major depressive episodes and the worrying link between methamphetamine use and immune system disruptions. The episode doesn't shy away from addressing broader social issues either.
It highlights a pilot study on reducing young adult alcohol use through dynamic norms interventions and discusses nalmefene as a potential alternative for reversing opioid overdoses. To top it off, there's a thought-provoking commentary on the biases faced by pregnant and postpartum individuals with substance use disorders within the healthcare system. Claire's engaging style and insightful commentary make complex research accessible and relevant.
Whether you're a healthcare professional, a student, or someone affected by addiction, this episode offers valuable knowledge and fresh perspectives. Don't miss out on this deep dive into the latest advancements in addiction medicine.